Skip to content
OpenCapital
Get started

Disc Medicine IRON Bitopertin — Research And Development Expense

Other product segments

Internal Research And Development
$11.31M+67.6%
DISC Three Four Zero Five
$9.19M+451%
DISC Zero Nine Seven Four
$8.11M+32.5%
Other Research
$2.17M+18.2%

Similar metrics at other companies

BioCryst Pharmaceuticals logo
BCRXBerotralstat — Research and Development Expense (Excluding Acquired in Process Cost)
$1.8M-4.2%
Scholar Rock logo
SRRKApitegromab — Research And Development Expense
$20.26M+5.0%
Stoke Therapeutics, Inc. logo
STOKOther Non Program Costs Research And Development — Operating Expenses
-$1.68M-19.4%
Tango Therapeutics logo
TNGXVopimetostat Direct Program Expenses-RD — Research And Development Expense
$9.33M+70.9%
BioCryst Pharmaceuticals logo
BCRXSTAR-0310 — Research and Development Expense (Excluding Acquired in Process Cost)
$683K—
Roivant Sciences logo
ROIVBrepocitinib — Research and development (includes $18,123and $9,685 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $40,218and $30,128 for the nine months ended December 31, 2025 and 2024, respectively)
$14.34M+9.7%

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0×0.0×
Current ratio24×-13.6×

Where this comes from

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's bitopertin — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's bitopertin — research and development expense?
Disc Medicine (IRON) reported bitopertin — research and development expense of $9.34M in Q1 2026.
How has Disc Medicine's bitopertin — research and development expense changed year-over-year?
Disc Medicine's bitopertin — research and development expense increased by 10.7% year-over-year, from $8.44M to $9.34M.
What is the long-term trend for Disc Medicine's bitopertin — research and development expense?
Over 2 years (2023 to 2025), Disc Medicine's bitopertin — research and development expense has grown at a 84.6% compound annual growth rate (CAGR), from $17.27M to $58.83M.
What does bitopertin — research and development expense mean?
This metric represents the total operating costs directly attributable to the research, clinical development, and regulatory advancement of the Bitopertin therapeutic candidate. It captures the investment intensity required to progress this specific asset through clinical trials and toward potential commercialization. Monitoring this expense helps investors assess the capital allocation strategy and the pace of development for this key pipeline asset.